

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort

C. H. Williams-Gray,¹ T. Foltynie,¹ C. E. G. Brayne,² T. W. Robbins³ and R. A. Barker¹

¹Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, ²Department of Public Health and Primary Care, University of Cambridge and ³Department of Experimental Psychology, University of Cambridge, UK

Correspondence to: Caroline Williams-Gray, MRCP, Cambridge Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 2PY, UK.
E-mail: chm27@cam.ac.uk

We have previously performed detailed clinical and neuropsychological assessments in a community-based cohort of patients with newly diagnosed parkinsonism, and through analysis of a subcohort with idiopathic Parkinson's disease (PD), we have demonstrated that cognitive dysfunction occurs even at the time of PD diagnosis and is heterogeneous. Longitudinal follow-up of the cohort has now been performed to examine the evolution of cognitive dysfunction within the early years of the disease. One hundred and eighty (79%) eligible patients from the original cohort with parkinsonism were available for re-assessment at between 3 and 5 years from their initial baseline assessments. PD diagnoses were re-validated with repeated application of the UKPDS Brain Bank criteria in order to maximize sensitivity and specificity, following which a diagnosis of idiopathic PD was confirmed in 126 patients. Thirteen out of 126 (10%) had developed dementia at a mean (SD) of 3.5 (0.7) years from diagnosis, corresponding to an annual dementia incidence of 30.0 (16.4–52.9) per 1000 person-years. A further 57% of PD patients showed evidence of cognitive impairment, with frontostriatal deficits being most common amongst the non-demented group. However, the most important clinical predictors of global cognitive decline following correction for age were neuropsychological tasks with a more posterior cortical basis, including semantic fluency and ability to copy an intersecting pentagons figure, as well as a non-tremor dominant motor phenotype at the baseline assessment. This work clarifies the profile of cognitive dysfunction in early PD and demonstrates that the dementing process in this illness is heralded by both postural and gait dysfunction and cognitive deficits with a posterior cortical basis, reflecting probable non-dopaminergic cortical Lewy body pathology. Furthermore, given that these predictors of dementia are readily measurable within just a few minutes in a clinical setting, our work may ultimately have practical implications in terms of guiding prognosis in individual patients.

Keywords: Parkinson's disease; cognitive; dementia; incidence

Abbreviations: PD = Parkinson's disease

Received December 16, 2006. Revised March 21, 2007. Accepted April 18, 2007. Advance Access publication May 29, 2007

Introduction

Although Parkinson's disease (PD) is defined classically in terms of its motor symptomatology, it has become apparent in recent years that non-motor deficits form an important part of the syndrome (Chaudhuri *et al.*, 2006). Dementia in particular is a common feature of the disease, with an estimated prevalence of between 24 and 31% (Aarsland *et al.*, 2005b). Furthermore, dementia has a major impact on quality of life (Schrag *et al.*, 2000) and prognosis (Nussbaum *et al.*, 1998), as well as being an important risk factor for nursing home placement (Aarsland *et al.*, 2000),

with consequent major health economics implications (Findley *et al.*, 2003). The underlying pathophysiology of PD dementia is thought to involve limbic and neocortical Lewy body deposition, although neurofibrillary tangles and senile plaques may play a role in some patients and dysfunction of non-dopaminergic neurotransmitter systems, in particular the cholinergic system, has also been heavily implicated (reviewed in Williams-Gray *et al.*, 2006).

Estimates of the incidence of dementia in PD have varied considerably (Table 1). However, a significant methodological problem with the majority of previous studies is the

Table 1 Summary of studies providing estimates of dementia incidence in PD

Reference	<i>n</i>	Age at inclusion, mean (SD)	Follow-up (years)	Design	Incidence (per 1000 person-years)	95% CI
Mayeux <i>et al.</i> (1990)	249	N/A	4.75	Hospital-based, ^a prevalent	69	n/a
Biggins <i>et al.</i> (1992)	82	64.1 (10.1)	4.5	Hospital-based, ^a prevalent	476	n/a
Marder <i>et al.</i> (1995)	140	71.1	3.5	Community-based, prevalent	112.5	n/a
Mahieux <i>et al.</i> (1998)	86	72.2 (8.2)	3.5	Hospital-based, ^a prevalent	67.2	40.3–105.1
Hughes <i>et al.</i> (2000)	83	63.7 (10.1)	9.3	Hospital-based, ^a prevalent	42.6	n/a
Aarsland <i>et al.</i> (2001)	130	69.8 (8.0)	4.2	Community-based, prevalent	95.3	68.2–122
Hobson <i>et al.</i> (2004)	51	74.2 (8.6)	4	Community-based, prevalent	107.1	59.9–159.8
Our study	126	69.6 (9.9)	3.5	Community-based, incident	30.0	16.4–52.9

^aIndicates recruitment from hospital outpatient clinics.

inclusion of prevalent patients at varying disease stages. Only one study has investigated the development of dementia in a newly diagnosed PD cohort followed longitudinally; 48% of surviving patients ultimately met criteria for dementia at 15 years, but annual incidence figures were not calculated (Hely *et al.*, 2005). Furthermore, this study and others used biased cohorts recruited from hospital outpatient clinics rather than the community (Mayeux *et al.*, 1990; Biggins *et al.*, 1992; Mahieux *et al.*, 1998; Hughes *et al.*, 2000). Accurate determination of the true natural history of cognitive dysfunction within PD requires detailed prospective longitudinal follow-up of an incident rather than prevalent cohort which is population-representative.

A further methodological concern in published studies investigating this issue in PD is the accuracy of dementia diagnosis. The majority of studies have used DSM criteria, essentially requiring the demonstration of memory impairment and higher cortical dysfunction which interfere significantly with social or occupational functional capacity (Diagnostic and Statistical Manual of Mental Disorders, 1994). Determination of whether or not a patient fulfils such criteria is subjective, and may differ substantially from centre to centre given that there is no standardized definition of 'impairment'. The adoption of an additional more objective criterion, such as a cut-off score on a standardized cognitive rating scale (MMSE <24 has been widely used, see Tangalos *et al.*, 1996), circumvents this problem to some extent. However, the MMSE is also affected by lack of standardization of administration between centres, and fulfilment of the criterion of a score below 24 may be confounded by a patient's pre-morbid IQ. Hence an alternative outcome variable based on repeated assessments and reflecting *rate* of cognitive decline may actually be a more useful and informative measure of cognitive dysfunction for the individual patient. We have calculated such a measure for our patients in addition to estimating dementia incidence using standard DSM-IV and MMSE-based criteria.

The cognitive dysfunction of PD encompasses a wide range of deficits, but perhaps the most well defined are executive in nature, affecting ability to plan, organize and

regulate goal-directed behaviour. Such deficits are demonstrable on frontally mediated tasks of working memory, planning and attentional set shifting (Owen *et al.*, 1992, 1995a). Performance is typically influenced by both levodopa therapy (Lange *et al.*, 1992; Owen *et al.*, 1995a; Cools *et al.*, 2001) and functional polymorphisms in genes involved in dopamine regulation (Foltnie *et al.*, 2004b), supporting the notion that executive deficits reflect dopaminergic dysfunction in frontostriatal networks. Verbal fluency deficits are also well described in PD, which in part reflect deficiencies in executive search and retrieval processes. However, a recent large meta-analysis has demonstrated that PD patients are more impaired on tests of semantic than phonemic fluency, implying that pathology in the temporal lobe might contribute to the observed fluency impairment (Henry and Crawford, 2004b). Further evidence for posterior cortically based deficits comes from studies describing explicit memory impairment (Helkala *et al.*, 1988; Pillon *et al.*, 1993) and visuospatial and constructional dysfunction in PD (Girotti *et al.*, 1988; Levin *et al.*, 1991; Pillon *et al.*, 1991; Aarsland *et al.*, 2003). Cognitive deficits in PD also seem to be heterogeneous in terms of their neurochemical basis. In particular, Dubois *et al.* (1987) have demonstrated that low-dose scopolamine causes impairment in visual recognition memory in patients with PD but not controls, implying that some cognitive deficits in PD are acetylcholine-dependent.

In terms of when such deficits arise in PD, it is clear that dysfunction across a range of neuropsychological domains occurs even in the earliest stages (Foltnie *et al.*, 2004a; Levin and Katzen, 2005; Muslimovic *et al.*, 2005). Our previous work has demonstrated that cognitive impairment is heterogeneous, with deficits exclusively in frontostrially based tasks in 12%, deficits in temporal lobe-based tasks in 8% and global deficits in 15% of a community-based cohort of 159 newly diagnosed patients (Foltnie *et al.*, 2004a), thus adding weight to the hypothesis that the neural substrates of these neuropsychological deficits are anatomically and/or neurochemically diverse. How these deficits in early disease relate to the later development of dementia is unclear, but in this study we have investigated this relationship through following up our incident cohort.

This is of the utmost importance for improving our understanding of the neural basis of PD dementia, as well as for identifying predictive markers of dementia to enable the implementation of therapeutic and supportive strategies at a stage of disease when they are more likely to be effective.

Previous attempts to determine early neuropsychological predictors of dementia have produced varied and inconsistent results: executive deficits (Mahieux *et al.*, 1998; Levy *et al.*, 2002a; Janvin *et al.*, 2005), impaired verbal fluency (Jacobs *et al.*, 1995; Mahieux *et al.*, 1998), visuospatial deficits (Mahieux *et al.*, 1998) and memory and language dysfunction (Levy *et al.*, 2002a; Hobson and Meara, 2004) have all been suggested as useful prognostic markers in longitudinal studies. Their findings are, of course, influenced by the particular selection of neuropsychological tests employed. Different 'executive' tests, for example, can vary considerably in terms of their cognitive demands. Furthermore, it is clear that no human neuropsychological test is uniquely associated with damage to a specific brain region. We have selected for our assessments a range of well-validated tests, including several items from the CANTAB battery (Owen *et al.*, 1990; Robbins *et al.*, 1994) which depend to varying degrees upon frontal, temporal and parietal lobe function. This approach enables us to characterize the profile of impairments in our cohort and estimate the type of dysfunction predominantly associated with subsequent cognitive decline and the development of dementia.

We have previously established a community-based incident PD cohort and described their clinical and neuropsychological characteristics at the time of diagnosis (Foltnie *et al.*, 2004a). In this study, we use outcome data from follow-up assessments between 3 and 5 years later to address three principal aims. These are: first, to estimate the incidence of dementia in early PD; secondly to redefine the profile of cognitive dysfunction in the disease; and finally, to determine which baseline clinical and neuropsychological variables best predict cognitive decline.

Material and Methods

A community-based cohort of 239 patients with incident parkinsonism was recruited within the county of Cambridgeshire, UK, over a 2-year period between December 2000 and December 2002 using multiple sources of case ascertainment. Full details of the recruitment process have been published elsewhere (Foltnie *et al.*, 2004a). All patients underwent comprehensive clinical and neuropsychological assessments at baseline. Follow-up assessments were conducted in patients' own homes over a 13-month period between December 2004 and December 2005 and comprised a repeat of the full baseline assessment and an evaluation of dementia status (see later).

Diagnosis of PD

One hundred and fifty-nine of the 239 recruited patients with parkinsonism were diagnosed with PD at baseline (Foltnie *et al.*,

2004a) using the UK Parkinson's Disease Society (UKPDS) Brain Bank criteria (Gibb and Lees, 1988). These criteria were reapplied at follow-up to the entire cohort, irrespective of initial diagnosis, to optimize diagnostic accuracy. Only those meeting a diagnosis of PD following this re-validation process were included in subsequent analyses of dementia incidence and factors predicting cognitive decline. Specifically, criteria for PD diagnosis were:

1. Fulfilment of the UKPDS Brain Bank criteria at baseline and follow-up assessments, or
2. Parkinsonism of uncertain cause at baseline and fulfilment of UKPDS Brain Bank criteria at follow-up, or
3. Suspected drug-induced parkinsonism at baseline but progression of symptoms despite discontinuation of the drug in question for >2 years and fulfilment of UKPDS Brain Bank criteria in other respects at follow-up.

Patients with suspected PD but significant cognitive impairment at baseline, i.e. an MMSE of <24 (Folstein *et al.*, 1975), were excluded from further analysis, thus minimizing the possibility of erroneously including patients with Dementia with Lewy Bodies in our cohort.

Clinical assessment

This included a full history of the disease and co-morbid conditions, drug history, family history of neurological disease and a standardized neurological assessment including the Unified Parkinson's Disease Rating Scale (Fahn and Elton, 1987) together with screening for atypical features pointing to other parkinsonian diagnoses. Patients were classified in terms of motor phenotype as 'tremor dominant', 'mixed' or 'postural instability and gait disturbance' (PIGD) on the basis of tremor and PIGD scores derived from the motor subsection of the UPDRS, as in previous studies (Zetuskus *et al.*, 1985; Jankovic *et al.*, 1990). All patients completed the Beck Depression Inventory (Beck *et al.*, 1961). Functional independence scores were assessed using the Schwab and England scale (Schwab and England, 1969).

Doses of dopaminergic medication were converted to equivalent levodopa doses using the following formula, developed from those previously used in the literature (Brodsky *et al.*, 2003). Equivalent levodopa dose = [levodopa ($\times 1.2$ if COMT inhibitor) ($\times 1.2$ if 10 mg selegiline OR $\times 1.1$ if 5 mg selegiline)] + [pramipexole $\times 400$] + [ropinirole $\times 40$] + [cabergoline $\times 160$] + [pergolide $\times 200$] + [bromocriptine $\times 10$] + [lisuride $\times 160$], all doses in mg.

Neuropsychological assessment

Patients underwent a battery of standardized, previously validated cognitive tests at both baseline (Foltnie *et al.*, 2004a) and follow-up. These included the following: the 30-item Mini-mental state examination (MMSE, Folstein *et al.*, 1975); the National Adult Reading Test (NART, a measure of verbal IQ, Nelson and O'Connell, 1978); a test of phonemic fluency for words starting with the letters F, A and S for 1 min each (Benton, 1968); a test of semantic fluency for animals in a 90-s period (Goodglass, 1972); selected computerized neuropsychological tests from the CANTAB battery including Pattern and Spatial Recognition Memory (PRM and SRM; Sahakian *et al.*, 1988) and the 'one-touch' Tower of London (TOL; Owen *et al.*, 1995a). In addition, the interlocking pentagon copying item within the MMSE was graded using a 0–2 rating scale modified from Ala *et al.* (2001) with 2 points indicating that all 10 angles were present and the 2 pentagons

were intersecting, 1 point indicating that two intersecting figures were present, one with 5 angles and 0 indicating a less-acceptable copy.

The neuropsychological battery was selected to probe frontal, temporal and parietal lobe function, although the individual tests cannot be fully segregated in terms of their neuroanatomical basis. In terms of verbal fluency, phonemic and semantic tests are thought to load differentially on frontal and temporal processing, with both tests being impaired to a similar extent by frontal lobe damage but semantic fluency being predominantly impaired by temporal damage (Henry and Crawford, 2004a). CANTAB PRM is sensitive to temporal lobe, but not frontal lobe lesions, whereas SRM shows the opposite pattern of sensitivity (Owen *et al.*, 1995b). Performance on the TOL, a test of planning and working memory, is also impaired in patients with frontal lobe damage (Owen *et al.*, 1990), and functional imaging studies have confirmed that the test reliably activates the prefrontal as well as parietal cortex (e.g. (Baker *et al.*, 1996; Lazeron *et al.*, 2000). Further evidence supporting the idea that the CANTAB tests depend on different neural circuits comes from levodopa withdrawal studies and cross-sectional comparisons of medicated and unmedicated patients. These studies suggest that levodopa has a beneficial effect on performance on the TOL and SRM tests (Lange *et al.*, 1992; Owen *et al.*, 1995a; Swainson *et al.*, 2000), but does not influence performance on the PRM test (Lange *et al.*, 1992), supporting the concept that deficits on the latter arise from posterior cortical circuitry rather than dopaminergic, frontostriatal circuitry.

Tasks involving figure copying are used to detect constructional apraxia, a common feature of both PD dementia and Dementia with Lewy Bodies (DLB) (Aarsland *et al.*, 2003; Cormack *et al.*, 2004). It is widely recognized that visuospatial and constructional deficits follow focal parietal lobe lesions (Di Renzi, 1997) and functional imaging studies have confirmed that picture copying in particular activates the parietal cortex (Makuuchi *et al.*, 2003). We selected the MMSE pentagon copying item as a constructional test for this study because it is widely utilized in a clinical setting and has been shown to be highly sensitive for distinguishing Lewy Body disease from Alzheimer's disease (Ala *et al.*, 2001).

A diagnosis of dementia at follow-up was made on the basis of an MMSE of less than 24 and fulfilment of DSM-IV criteria for dementia. Although the DSM-IV criteria rely on subjective judgements, their application was standardized as much as possible. Specifically, criterion A, requiring memory impairment plus impairment of at least one other 'higher cortical function' was evaluated using pre-defined cut-off values on our neuropsychological test battery (see later). Criterion B, relating to impairment of occupational and social functioning, required a functional independence score on the Schwab and England scale of less than or equal to 60% (denoting inability to perform certain activities of daily living) although some subjective judgement was required to determine whether this disability was attributable to cognitive rather than motor impairment.

Data analysis

Dementia incidence was calculated using the person-years method, i.e. by dividing the number of cases of dementia by the total number of 'at risk' person-years of follow-up. For non-demented patients, the number of 'at risk' years was simply the time period between assessments in years. For cases of incident dementia, time

of dementia onset was assumed to be the midpoint of the interval between assessments, hence the number of 'at risk' years was calculated by halving the time interval between assessments (Aarsland *et al.*, 2001). This analysis was restricted to those patients with a 'definite' diagnosis of PD, i.e. those whose diagnosis had been re-validated at follow-up. We did not attempt to adjust for mortality given that it was impossible to retrospectively determine a patient's cognitive status in the period immediately prior to their death with any certainty.

Amongst those not meeting criteria for dementia, the proportion of patients scoring below a specified cut-off value was calculated for each test to allow the profile of mild cognitive impairments at follow-up to be determined. Similar cognitive profiling was performed retrospectively for baseline assessments for comparison with follow-up data. For the CANTAB tests, pre-defined cut-offs for impairment were adopted, as in our previous studies (Lewis *et al.*, 2003; Foltynie *et al.*, 2004a), i.e. number correct <14/20 for the SRM, <16/20 for the PRM and <8/14 for the TOL. These cut-off scores were defined as 1 SD below normative means in age and IQ-matched samples of healthy controls. Normative data for the PRM and SRM were provided by Cambridge Cognition, UK and for the 'one-touch' TOL these data were collected locally (Sahakian *et al.*, unpublished data). Phonemic fluency impairment was defined as a score below a cut-off of 1 SD below the mean in age-matched controls, i.e. <25 words in 3 min (Tombaugh *et al.*, 1999). The semantic fluency cut-off of 16 words in 90 s was derived from normative data (Tombaugh *et al.*, 1999) in a similar fashion, adjusted by a factor of 1.2 to account for the fact that our animal-naming scores were collected over 90 rather than 60 s (which is associated with a mean score increment of 20% according to our unpublished data). Pentagon copying was considered to be impaired if a score of less than 2 was obtained.

In order to accurately identify predictors of cognitive decline and dementia, we used a rigorous and systematic approach of analysis encompassing two complementary outcome measures. In the first stage of analysis, change in MMSE per year, calculated by dividing the difference in MMSE scores at baseline and follow-up by the time interval between assessments, was adopted as an outcome variable. This continuous variable was selected rather than development of dementia *per se* in order to optimize power, given that the number of patients developing dementia at 3.5 years was small. Furthermore, as previously discussed, this variable could be argued to be more clinically relevant to individuals than meeting criteria for dementia. Simple bivariate analyses were performed to identify potential predictors of cognitive decline. Non-categorical clinical and neuropsychological variables from the baseline assessment were dichotomized at the median. Between-group comparisons were made using Student's *t* tests or one-way ANOVA. In the second stage of analysis, baseline variables significantly associated with cognitive decline in the bivariate analyses ($P \leq 0.05$) were entered into a multivariate regression analysis, again using change in MMSE per year as the dependent variable. A backward stepwise method was employed such that all potential predictor variables were entered into the model, and non-significant predictors ($P < 0.10$) were removed in a stepwise fashion. In the third stage of analysis, we sought to confirm an association between identified predictors of cognitive decline and the alternative outcome variable of dementia. Bivariate analyses were used, with the calculation of relative risks where appropriate. All analyses were conducted using SPSS version 11.5.

Results

Re-validation of diagnoses

Figure 1 summarizes the number and outcome of follow-up assessments conducted at a mean (SD) time from diagnosis of 3.5 (0.7) years. Ten patients from the original group with PD diagnosed according to the UKPDS Brain Bank criteria ('PDBB') had an MMSE of <24 at baseline. Retrospective application of DSM-IV criteria confirmed that they were demented at presentation, hence this subgroup were excluded from subsequent analyses. A further 14 patients from the 'PDBB' group died prior to the follow-up assessment. These patients were significantly older ($P=0.01$) and had lower Schwab and England scores ($P=0.02$) indicating more functional impairment than those assessed, but they did not differ in terms of gender or baseline UPDRS, MMSE or Beck depression scores (Supplementary Table 1). Those lost to follow-up from the 'PDBB' group ($n=7$) did not differ significantly from those assessed on any of these variables (Supplementary Table 1). Re-validation of diagnoses through repeated application of the UKPDS Brain Bank criteria resulted in the exclusion of 12 patients from the original PD group, thus the criteria had a positive predictive value for a 'definite' PD diagnosis at follow-up of 90%. Of those with undefined parkinsonism at baseline, six fulfilled UKPDS Brain Bank criteria at follow-up, and a further six from the 'drug-induced' group also now met diagnostic criteria for PD (all had progressive symptoms for >2 years post

discontinuation of the drug in question), corresponding to negative predictive values of 50 and 66.6% for the criteria in these groups respectively. No patients with baseline diagnoses of Essential Tremor, Dystonic Tremor, Corticobasal Degeneration, Multiple System Atrophy, Dementia with Lewy Bodies or Vascular Parkinsonism met PD diagnostic criteria at follow-up, indicating a negative predictive value for the criteria of 100% in these patients. One hundred and twenty-six patients in total were included in the 'PDBB' group at 3.5 years and are included in our subsequent analyses.

Dementia incidence

Thirteen (10%) out of 126 patients met DSM-IV criteria for dementia at the follow-up assessment. Eleven of these had MMSE scores below 24. The remaining two had MMSE scores equal to 24, on the borderline of the arbitrary cut-off, hence it was deemed appropriate to also include them within the dementia group. There were no additional patients with MMSE-defined dementia who did not meet DSM-IV criteria. The estimated annual incidence of dementia was 30.0 per 1000 person-years of observation (95% confidence intervals 16.4–52.9 per 1000 person years). Exclusion of the 12 patients whose PD diagnosis was not established until the follow-up assessment did not alter the dementia incidence estimate (one case of dementia was diagnosed amongst this group).




Fig. 1 Flow-chart summarizing the re-validation of diagnoses in a cohort of 239 patients with incident parkinsonism based on the outcome of follow-up assessments conducted at a mean (SD) time of 3.5 (0.7) years from baseline. 'PDBB' indicates a diagnosis of PD according to the UKPDS Brain Bank criteria. 'Other' parkinsonism indicates a diagnosis of Dystonic Tremor, Corticobasal Degeneration, Multiple System Atrophy, Dementia with Lewy Bodies or Vascular Parkinsonism. 'Drug-induced' indicates parkinsonism in the context of recent exposure to a neuroleptic drug; this diagnosis was revised at follow-up only if parkinsonism had progressed despite omission of the drug in question for a period of >2 years. 'Unspecified' indicates evidence of parkinsonism but with no clear diagnosis. 'ET' indicates essential tremor. *patient unable to complete assessment due to recent major cerebrovascular event.




Fig. 2 Profile of cognitive dysfunction amongst PD patients at baseline and at 3.5 (+/−0.7) years from diagnosis. **(A)** Percentage of the cohort ($n = 126$) with cognitive dysfunction. Mild impairment = deficit on at least one neuropsychological test, but criteria for dementia not met. **(B)** Distribution of impairments across the neuropsychological battery amongst non-demented patients ($n = 126$ at baseline, $n = 113$ at follow-up). SRM = Spatial Recognition Memory, TOL = Tower of London, PF = phonemic fluency, SF = semantic fluency, PRM = Pattern Recognition Memory, pentagons = pentagon copying.

Profile of cognitive impairment

At baseline, 62% of patients were impaired on at least one neuropsychological test. The overall proportion of patients with cognitive dysfunction was similar at 3.5 years, although 10% now met criteria for dementia. Amongst non-demented patients, deficits on SRM and TOL, which depend at least partially on frontal processing, were more common at the second assessment, whereas deficits on the more temporal lobe-based PRM were less common (Fig. 2). The subgroup with dementia exhibited a global pattern of cognitive deficits, with 12/13 being impaired on pentagon copying, 11/13 being impaired on phonemic fluency, and all being impaired on semantic fluency. Nine of 13 were unable to complete the CANTAB battery due to inability to comprehend the instructions for the tasks.

Risk factors for cognitive decline

Rate of change of MMSE ranged from +1.4 to −6.8 points per year (mean −0.3 +/− 0.1). No other relevant co-morbid conditions were identified to account for the most extreme rates of cognitive decline. There was a clear relationship between change in MMSE and age, with a particular susceptibility to cognitive decline over 70 years (Fig. 3). Bivariate comparisons of baseline demographic, clinical and neuropsychological variables versus rate of cognitive decline are shown in Table 2. In addition to older age, a non-tremor dominant motor phenotype, a higher UPDRS motor score, and below average performance on tests of semantic fluency, pentagon copying, SRM and TOL were associated with a more rapid rate of cognitive decline ($P < 0.05$) and were therefore selected for inclusion in a multivariate analysis.




Fig. 3 Distribution of rate of cognitive change (change in MMSE per year) as a function of age in the PD cohort ($n = 126$). Kendall's tau-b correlation coefficient = −0.21, $P = 0.001$.

Multivariate analysis revealed that a non-tremor dominant motor phenotype, poor semantic fluency and inaccurate pentagon copying were the most significant predictors of cognitive decline, independently of age (Table 3). Inclusion of estimated IQ (NART) as a potential confounding factor in the multivariate model did not significantly change the outcome. Cross-group comparisons suggested that these predictor variables were associated with dementia risk *per se* in addition to an increased rate of cognitive decline (Table 4). Patients with a non-tremor dominant phenotype were 4.1 times more likely to develop dementia than tremor-dominant patients, and those who were unable to accurately copy intersecting pentagons were 5.2 times more likely to dement. Verbal fluency deficits were stratified to differentiate between semantic and phonemic impairments. Whereas isolated semantic and global deficits were associated with a significantly increased

Table 2 Bivariate comparisons of baseline demographic, clinical and neuropsychological variables versus rate of cognitive decline (change in MMSE per year) using Student's *t* test (2 categories) or ANOVA (>2 categories)

Variable	Change in MMSE/year		P-value
	Mean	SD	
Age			
<72	−0.01	0.50	0.001
≥72	−0.61	1.33	
Gender			
male	−0.35	0.99	0.59
female	−0.25	1.10	
Motor phenotype ^a			
tremor dominant	−0.01	0.57	0.002
mixed/PIGD	−0.53	1.24	
UPDRS motor score			
<25 ^b	−0.07	0.71	0.01
≥25	−0.52	1.24	
Equivalent levodopa dose			
0	−0.28	1.12	0.32
1–250	−0.35	1.14	
251–500	−0.64	1.02	
501–750	0.11	0.60	
751–1000	−0.14	0.32	
NART ^c (IQ)			
<112	−0.31	0.83	0.76
≥112	−0.26	1.23	
Phonemic fluency (FAS)			
<34	−0.49	0.97	0.06
≥34	−0.13	1.09	
Semantic fluency (animals)			
<20	−0.62	1.35	0.001
≥20	−0.01	0.48	
Pattern recognition memory score			
<19	−0.46	1.29	0.17
≥19	−0.19	0.83	
Spatial recognition memory score			
<15	−0.57	1.36	0.05
≥15	−0.13	0.75	
Tower of London score			
<10	−0.62	1.32	0.01
≥10	−0.07	0.77	
Pentagon copying score			
0	−1.21	0.89	0.03
1	−0.52	1.82	
2	−0.21	0.85	
Beck depression score			
<7	−0.26	1.14	0.09
≥7	−0.35	0.94	

Note: Continuous variables are dichotomized at the median, with the exception of levodopa dose, which is stratified into five subgroups.

^aPreliminary analyses suggested similar rates of cognitive decline in PIGD and mixed subgroups, hence these were combined into a single subgroup for analysis.

^bUnified Parkinson's Disease Rating Scale.

^cNational Adult Reading Test.

Table 3 Multivariate regression model with change in MMSE per year as the dependent variable; $F = 6.79$, $P < 0.001$, $R^2 = 0.195$

Variable	B coefficient	P value
Constant	−0.76	0.04
Age ≥72	−0.38	0.05
Non-tremor-dominant motor phenotype	−0.35	0.07
Pentagon copying score	−0.35	0.05
Semantic fluency <20	−0.38	0.05

Note: Baseline variables significantly associated with cognitive decline in the bivariate analyses ($P \leq 0.05$, see Table 2) were entered into the multivariate regression model and a backward stepwise method was employed to exclude non-significant variables (see 'Material and Methods' section).

dementia risk (RR 9.5 and 9.4 respectively, reference group unimpaired), isolated phonemic deficits were not, thus implicating the semantic component of the fluency task in particular in predicting dementia.

Discussion

In a population-based cohort of 126 patients with incident PD followed up for a mean of 3.5 years, we have shown that dementia occurs at an estimated incidence rate of 30.0 per 1000 person-years. In addition to the 10% of patients meeting criteria for dementia at follow-up, a further 57% showed some degree of impairment on neuropsychological testing, hence two-third of the cohorts were cognitively impaired at 3.5 years. Through a systematic approach of analysis we have identified a number of clinical predictors of cognitive decline independent of age, including a non-tremor-dominant motor phenotype, impaired semantic fluency and impaired pentagon copying at presentation.

The major strengths of this longitudinal study lie in the nature of the cohort: it is incident, rather than cross-sectional, thus allowing us to monitor the evolution of cognitive dysfunction throughout the course of the disease, and it is community-based, thus representative of the true spectrum of PD within the population. These unique features are likely to account for the disparity between our estimate of dementia incidence in PD and previous estimates (Table 1). Our incidence figure, although lower than in other studies, is still notably higher than the dementia incidence rate for UK population at a comparable age: the MRC Cognitive Function and Ageing study (Matthews and Brayne, 2005) estimates a dementia incidence of 10.3 (95% CI 6.2–19.9) at age 70–74 years, the mean age of our cohort. It is possible that dementia incidence might increase with disease duration in PD, thus the low incidence in our cohort might reflect early disease stage. However, the population-based Rotterdam study reported no increase in hazard ratio for dementia with increasing disease duration in 166 PD dementia cases,

Table 4 Baseline predictor variables and relative risks of developing dementia at 3.5 years

Variable	Dementia			RR (95% CI)
	No (n = 113)	Yes (n = 13)	P	
Age at diagnosis [mean (SD)]	68.3 (9.9)	77.6 (6.2)	0.001 ^a	n/a
Motor phenotype				
Tremor dominant	52	2	0.041 ^b	Ref
Mixed/PIGD	61	11		4.1 (1.0–17.8)
Pentagon copying				
Accurate (score ≥ 2)	97	6	0.002 ^b	Ref
Inaccurate (score < 2)	16	7		5.2 (1.9–14.1)
Verbal fluency				
No impairment	73	2	ref	Ref
Isolated phonemic deficit ^c	13	2	0.131 ^b	n/a
Isolated semantic deficit ^d	12	4	0.008 ^b	9.5 (1.9–47.5)
Global deficit ^e	15	5	0.002 ^b	9.4 (2.0–44.8)

Note: ref = reference category for comparison.

^aStudent's *t* test.

^bFisher's exact test.

Verbal fluency deficits defined as performance <1 SD below mean (^cphonemic score <25 and semantic score ≥16; ^dsemantic score <16 and phonemic score ≥25; ^esemantic score <16 and phonemic score <25).

although the majority of these were established rather than incident cases hence subject to recruitment bias (de Lau *et al.*, 2005). Further longitudinal follow-up of our incident cohort should resolve this question, allowing estimation of disease duration-specific incidence rates for dementia in PD.

A further strength of this study is the rigorous process applied to define PD cases. We used the UKPDS Brain Bank criteria (Gibb and Lees, 1988), estimated in a clinicopathological study to have a diagnostic accuracy of 90% (Hughes *et al.*, 2001). Furthermore, given that diagnoses made at a single time point are likely to be less accurate than those made on the basis of longitudinal data, we followed up our entire cohort of parkinsonian patients to 3.5 years, and reapplied the same diagnostic criteria to all patients for a second time. Through this process we identified 12 patients with false positive PD diagnoses at presentation (10%) and a further 12 patients with false negative diagnoses (40% of unspecified/'drug-induced' group), thus we were able to optimize specificity and sensitivity of diagnosis at follow-up. Although this process resulted in the inclusion of 12 patients in the final cohort who were 'officially' diagnosed with PD at a later time than the other 114, all 12 had significant parkinsonian symptoms at baseline, and comparison of mean baseline UPDRS motor scores in this group versus the 114 meeting UKPDS Brain Bank criteria at both assessments revealed no significant difference (27.0 versus 25.4, respectively, $P = 0.97$, Mann–Whitney *U* test). Furthermore, given that the association between clinical signs and pathological stage is unclear in PD, time of diagnosis is a somewhat arbitrary measure.

One concern with all longitudinal studies of this type is attrition, which potentially introduces bias. In our study 21% of 229 eligible patients were not available for

follow-up, principally due to death (15%), whilst 7% were uncontactable or withdrew consent. We suspect that bias due to attrition was minimal as amongst the subcohort with 'definite' PD at baseline, the seven patients lost to follow-up did not differ clinically from those assessed. The 14 patients who died within this group were not surprisingly significantly older and had more functional impairment, probably reflecting their greater comorbidity, but notably did not differ from those assessed in terms of their baseline MMSE scores (Supplementary Table 1). Amongst the group with possible or 'drug-induced' parkinsonism at baseline, there was an attrition rate of 23%. However, through applying the expected negative predictive values of the UKPDS Brain Bank criteria in these groups of 50 and 66.6%, respectively, we anticipate that this degree of attrition would have led to the loss of only four true PD cases from the cohort.

Studies describing cognitive dysfunction in PD tend to focus on the development of dementia, although it is important to establish the frequency of milder degrees of cognitive impairment, which also impact significantly on quality of life (Frank *et al.*, 2006). The cognitive profile of this cohort has previously been described at baseline, when performance on three tests, namely the MMSE, PRM and TOL, was used to divide patients into subgroups with suspected frontostriatal impairment, temporal lobe type impairment, global impairment and no impairment (Foltynie *et al.*, 2004a). Preliminary analysis of our follow-up data, however, revealed that these subgroups were uninformative in terms of predicting cognitive outcome. This is not particularly surprising given that first, numbers within each subgroup were small, and secondly, the tests used to determine subgroups were chosen arbitrarily, without the benefit of longitudinal data, with the purpose of simply establishing that the cohort was

cognitively heterogeneous. Here, we adopted an alternative approach to describe the profile of cognitive dysfunction, based on the proportion of patients impaired on each test. This profiling (Fig. 2) reveals little change in the overall proportion of patients with cognitive impairment at follow-up versus baseline (67 versus 62%) but illustrates a change in the pattern of impairments: dementia develops in 10% and amongst the remaining non-demented patients, frontostrially based impairments become more frequent whilst deficits on the more temporal lobe-based PRM become less frequent with time. This may indicate the beginnings of a segregation of demented and non-demented patients in terms of their cognitive profiles, but further longitudinal data needs to be collected to explore this possibility. Alternative neuropsychological tools would be necessary to adequately probe the pattern of cognitive deficits amongst the demented group given that 9/13 were unable to complete the CANTAB PRM, SRM and TOL. These particular tests were primarily chosen to probe deficits amongst those with mild cognitive impairment and may require a threshold level of attentional capacity and short-term recall which some of our demented patients were unable to meet.

One of our key aims was to determine early clinical predictors of cognitive decline in PD. Age has consistently been demonstrated to be an important predictor of both dementia (Mahieux *et al.*, 1998; Aarsland *et al.*, 2001; Levy *et al.*, 2002b; Hobson and Meara, 2004) and cognitive decline (Aarsland *et al.*, 2004), and our study is in agreement with this finding. We have also identified three further predictors which influence rate of cognitive decline independently of age, namely motor phenotype, semantic fluency and pentagon copying performance. In addition, each of these predictors significantly increased the risk of meeting dementia criteria at 3.5 years, although the confidence intervals for the relative risk estimates were wide as a consequence of the small numbers with dementia at follow-up. Nonetheless, these RR estimates provide a preliminary indication of the value of these variables in predicting dementia. The predictors are particularly informative in combination, thus 62.5% (5/8) of patients with all three identified risk factors developed dementia versus none of the 39 patients with no such risk factors.

The association between motor symptom type and the development of cognitive impairment in PD has been examined previously. Our own cross-sectional cluster analysis of 120 PD patients identified a non-tremor dominant subgroup with significant cognitive impairment and a cognitively unimpaired tremor-dominant group (Lewis *et al.*, 2005). In longitudinal studies, axial and speech impairments have been associated with incident dementia (Levy *et al.*, 2000) and a more rapid rate of cognitive decline (Aarsland *et al.*, 2004), as has PIGD motor phenotype (Burn *et al.*, 2006). Furthermore, recent evidence suggests a temporal relationship between the development of PIGD symptoms and occurrence of dementia (Alves

et al., 2006). Hence our results, suggesting an association between non-tremor-dominant phenotypes and increased rate of cognitive decline, which still approaches significance in a multivariate model with correction for age, are broadly in keeping with those in the literature. It is possible that axial symptoms and PD dementia have overlapping aetiopathologies, with distinct loci of dysfunction different from those underlying tremor-dominant PD. Specifically, the postural instability of PD tends to be refractory to dopaminergic therapy, and may relate to dysfunction within the cholinergic system (Burn *et al.*, 2003) which also seems to play an important role in the dementia of PD (Whitehouse *et al.*, 1983; Perry *et al.*, 1985; Hilker *et al.*, 2005).

Verbal fluency impairment is well described in PD (Henry and Crawford, 2004b), and several other authors have identified fluency deficits as predictors of later-occurring dementia (Jacobs *et al.*, 1995; Mahieux *et al.*, 1998; Levy *et al.*, 2002a), though phonemic rather than semantic fluency has typically been implicated (Mahieux *et al.*, 1998; Levy *et al.*, 2002a). There is clearly a degree of overlap in terms of the underlying neurobiological basis of phonemic and semantic fluency deficits, with both relying on frontally based executive strategies. However, a difference in relative performance on the two tasks may be useful in terms of neuroanatomical localization, given that a disproportionate impairment of semantic fluency is seen in Alzheimer's disease and semantic dementia (Hodges *et al.*, 1992), in contrast to more prominent phonemic fluency deficits in subcortical dementias (Green, 2000). Furthermore, lesion studies indicate that temporal lobe damage produces significantly greater deficits in semantic compared to phonemic fluency, whereas frontal lobe lesions produce more comparable semantic and phonemic deficits (Henry and Crawford, 2004a). These observations probably reflect a reliance of semantic fluency on semantic memory, whose neural substrate is widely accepted to lie within the temporal lobe. Indeed, a functional imaging study has confirmed activation of the left medial temporal lobe during a category fluency task in contrast to a number listing task (Pihlajamaki *et al.*, 2000). Hence our finding that semantic but not phonemic fluency is a useful predictor of cognitive decline and dementia in PD has interesting implications with regard to the site of pathology in PD dementia, implying a posterior cortical rather than frontostriatal basis.

However, some studies have suggested that the relationship between fluency performance and neuroanatomical site of pathology is more complex [reviewed in (Troyer *et al.*, 1998a)]. Hence the number of words generated within a specific time may not be the most informative measure in this respect, but rather 'clustering' (i.e. producing clusters of semantically or phonemically related words) and 'switching' (i.e. shifting from one subcategory of words to another) may correlate more specifically with lesion site. Specifically, frontal lobe patients tend to be impaired on

switching during phonemic fluency tasks, whereas temporal lobe patients tend to generate smaller clusters of words during semantic fluency tasks (Troyer *et al.*, 1998a). The same pattern is claimed by these authors for PD dementia and Alzheimer's disease, respectively (Troyer *et al.*, 1998b), implying that PD dementia is a frontal rather than temporal lobe syndrome, in contrast to our findings. This discrepancy may relate to the definition of 'dementia' in their study: this was based on Dementia Rating Scale score alone, with no reference to functional disability, which is generally recognized as a key component of the dementia syndrome. Their PD dementia group may actually be comparable to our non-demented but cognitively impaired group, in whom frontally based deficits certainly do appear to be more prominent. Whilst further investigation of the prognostic significance of clustering and switching performance is warranted, one clear advantage of the more simplistic measure of 'number of words generated' is its ease of use in general clinical practice. Furthermore, irrespective of its underlying neural basis, this measure does appear to predict cognitive decline in PD.

The apparent utility of pentagon copying, a measure of visuospatial and constructional ability, as another predictor of cognitive decline in PD is not unexpected given that such deficits are prominent in DLB (Ala *et al.*, 2001; Tiraboschi *et al.*, 2006) and PD dementia (Cormack *et al.*, 2004). Other authors have similarly reported that constructional deficits predict dementia in PD (Mahieux *et al.*, 1998) and it is widely accepted that these deficits reflect parietal lobe dysfunction (Di Renzi, 1997; Makuuchi *et al.*, 2003). These clinical observations, together with recent post-mortem data (Aarsland *et al.*, 2005a), provide strong support for the hypothesis that the dementia of PD has a posterior cortical basis. Although Lewy body deposition seems the most likely aetiological factor, the extent to which posterior cortically based deficits are influenced by subcortical dopaminergic and cholinergic systems remains unresolved given that these cortical areas receive innervation from both systems (Berger *et al.*, 1991; Hurd *et al.*, 2001).

In conclusion, we have established through prospective follow-up of an incident population-based cohort that two-thirds of patients with early PD develop cognitive deficits within 3.5 (+/−0.7) years from disease onset. These deficits include both frontostrially based and more posterior cortical impairments, and 10% develop a global dementia. Furthermore, we have demonstrated that age, a non-tremor-dominant motor phenotype, and poor performance on two simple neuropsychological tests, namely semantic fluency and pentagon copying, are useful predictors of global cognitive decline. These predictors are particularly valuable in that they are all readily measurable within just a few minutes in an outpatient clinic setting. Thus this unique prospective study of an incident PD cohort using a rigorous process of assessment and analysis not only adds

to our understanding of the cognitive heterogeneity of PD and the basis of PD dementia, but its findings have practical prognostic implications for clinical practice.

Supplementary material

Supplementary material is available at *BRAIN* online.

Acknowledgements

We would like to dedicate this paper to the memory of Imogen Rose Barker, who inspired us to do so much, and who was sadly killed on February 24, 2007 aged 15 years. The work was supported by grants from the Medical Research Council and the Parkinson's Disease Society. C.H.W.G. is a Patrick Berthoud Clinical Research Fellow, and holds a Raymond and Beverly Sackler Studentship.

References

- Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 1994.
- Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. *Neurology* 2001; 56: 730–6.
- Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, et al. The rate of cognitive decline in Parkinson disease. *Arch Neurol* 2004; 61: 1906–11.
- Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based- prospective study. *J Am Geriatr Soc* 2000; 48: 938–42.
- Aarsland D, Litvan I, Salmon D, et al. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2003; 74: 1215–20.
- Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. *Ann Neurol* 2005a; 58: 773–6.
- Aarsland D, Zaccari J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. *Mov Disord* 2005b; 20: 1255–63.
- Ala TA, Hughes LF, Kyrrouac GA, Ghobrial MW, Elble RJ. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2001; 70: 483–8.
- Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. *Mov Disord* 2006; 21: 1123–30.
- Baker SC, Rogers RD, Owen AM, Frith CD, Dolan RJ, Frackowiak RS, et al. Neural systems engaged by planning: a PET study of the Tower of London task. *Neuropsychologia* 1996; 34: 515–26.
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961; 4: 561–71.
- Benton AL. Differential behavioural effects of frontal lobe disease. *Neuropsychologia* 1968; 6: 53–60.
- Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. *Trends Neurosci* 1991; 14: 21–7.
- Biggins CA, Boyd JL, Harrop FM, Madeley P, Mindham RH, Randall JJ, et al. A controlled, longitudinal study of dementia in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1992; 55: 566–71.
- Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. *Mov Disord* 2003; 18: 668–72.
- Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease

- with dementia, and dementia with Lewy bodies. *J Neurol Neurosurg Psychiatry* 2006; 77: 585–9.
- Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, et al. Extrapramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. *Mov Disord* 2003; 18: 884–9.
- Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol* 2006; 5: 235–45.
- Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. *Cereb Cortex* 2001; 11: 1136–43.
- Cormack F, Aarsland D, Ballard C, Tovee MJ. Pentagon drawing and neuropsychological performance in dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. *Int J Geriatr Psychiatry* 2004; 19: 371–7.
- de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. *Arch Neurol* 2005; 62: 1265–9.
- Di Renzi E. Visuospatial and constructional disorders. In: Feinberg TE, Farah MJ, editors. *Behavioural neurology and neuropsychology*. New York: McGraw-Hill; 1997. p. 297–307.
- Dubois B, Danze F, Pillon B, et al. Cholinergic-dependent cognitive deficits in Parkinson's disease. *Ann Neurol* 1987; 22: 26–30.
- Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. *Recent developments in Parkinson's disease*. Florham Park (NJ): MacMillan Healthcare Information; 1987. p. 153–63.
- Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. *Mov Disord* 2003; 18: 1139–45.
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189–98.
- Foltnie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. *Brain* 2004a; 127: 550–60.
- Foltnie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. *Mov Disord* 2004b; 19: 885–91.
- Frank L, Lloyd A, Flynn JA, Kleinman L, Matza LS, Margolis MK, et al. Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. *Int Psychogeriatr* 2006; 18: 151–62.
- Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1988; 51: 745–52.
- Girotti F, Soliveri P, Carella F, et al. Dementia and cognitive impairment in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1988; 51: 1498–502.
- Goodglass H. The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger; 1972.
- Green J. Neuropsychological evaluation of the older adult. A clinician's guidebook. San Diego: Academic Press; 2000.
- Helkala EL, Laulumaa V, Soininen H, et al. Recall and recognition memory in patients with Alzheimer's and Parkinson's disease. *Ann Neurol* 1988; 24: 214–7.
- Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. *Mov Disord* 2005; 20: 190–9.
- Henry JD, Crawford JR. A meta-analytic review of verbal fluency performance following focal cortical lesions. *Neuropsychology* 2004a; 18: 284–95.
- Henry JD, Crawford JR. Verbal fluency deficits in Parkinson's disease: a meta-analysis. *J Int Neuropsychol Soc* 2004b; 10: 608–22.
- Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. *Neurology* 2005; 65: 1716–22.
- Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. *Mov Disord* 2004; 19: 1043–9.
- Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. *Brain* 1992; 115 (Pt 6): 1783–806.
- Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. *Neurology* 2001; 57: S34–8.
- Hughes TA, Ross HF, Musa S, Bhattacharjee S, Nathan RN, Mindham RH, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. *Neurology* 2000; 54: 1596–602.
- Hurd Y, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. *J Chem Neuroanat* 2001; 22: 127–37.
- Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. *Neurology* 1995; 45: 1691–6.
- Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. *Neurology* 1990; 40: 1529–34.
- Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. *J Geriatr Psychiatry Neurol* 2005; 18: 149–54.
- Lange KW, Robbins TW, Marsden CD, et al. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. *Psychopharmacology* 1992; 107: 394–404.
- Lazeron RH, Rombouts SA, Machielsen WC, Scheltens P, Witter MP, Uylings HB, et al. Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. *AJNR Am J Neuroradiol* 2000; 21: 1407–14.
- Levin BE, Katzen HL. Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. *Adv Neurol* 2005; 96: 84–94.
- Levin BE, Llabre MM, Reisman S, et al. Visuospatial impairment in Parkinson's disease. *Neurology* 1991; 41: 365–9.
- Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaró B, et al. Memory and executive function impairment predict dementia in Parkinson's disease. *Mov Disord* 2002a; 17: 1221–6.
- Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. *Ann Neurol* 2002b; 51: 722–9.
- Levy G, Tang MX, Cote LJ, Louis ED, Alfaró B, Mejia H, et al. Motor impairment in PD: relationship to incident dementia and age. *Neurology* 2000; 55: 539–44.
- Lewis SJ, Cools R, Robbins TW, Barker RA, Owen AM. Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. *Neuropsychologia* 2003; 41: 645–54.
- Lewis SJ, Foltnie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. *J Neurol Neurosurg Psychiatry* 2005; 76: 343–8.
- Mahieux F, Fenelon G, Flahault A, Manificier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1998; 64: 178–83.
- Makuuchi M, Kaminaga T, Sugishita M. Both parietal lobes are involved in drawing: a functional MRI study and implications for constructional apraxia. *Brain Res Cogn Brain Res* 2003; 16: 338–47.
- Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. *Arch Neurol* 1995; 52: 695–701.

- Matthews F, Brayne C. The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study. *PLoS Med* 2005; 2: e193.
- Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. *Neurology* 1990; 40: 1513–7.
- Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. *Neurology* 2005; 65: 1239–45.
- Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. *Cortex* 1978; 14: 234–44.
- Nussbaum M, Treves TA, Inzelberg R, et al. Survival in Parkinson's disease: the effect of dementia. *Parkinsonism Related Disord* 1998; 4: 179–81.
- Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. *Neuropsychologia* 1990; 28: 1021–34.
- Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. *Brain* 1992; 115: 1727–51.
- Owen AM, Sahakian BJ, Hodges JR, Summers BA, Polkey CE, Robbins TW. Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease. *Neuropsychologia* 1995a; 9: 126–40.
- Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. *Neuropsychologia* 1995b; 33: 1–24.
- Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 1985; 48: 413–21.
- Pihlajamaki M, Tanila H, Hanninen T, Kononen M, Laakso M, Partanen K, et al. Verbal fluency activates the left medial temporal lobe: a functional magnetic resonance imaging study. *Ann Neurol* 2000; 47: 470–6.
- Pillon B, Deweer B, Agid Y, et al. Explicit memory in Alzheimer's, Huntington's and Parkinson's disease. *Arch Neurol* 1993; 50: 374–9.
- Pillon B, Dubois B, Ploska A, et al. Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. *Neurology* 1991; 41: 634–43.
- Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. *Dementia* 1994; 5: 266–81.
- Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. *Brain* 1988; 111 (Pt 3): 695–718.
- Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? *J Neurol Neurosurg Psychiatry* 2000; 69: 308–12.
- Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, editors. *Third Symposium on Parkinson's disease*. Edinburgh: E&S Livingstone; 1969. p. 152–7.
- Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. *Neuropsychologia* 2000; 38: 596–612.
- Tangalos EG, Smith GE, Ivnik RJ, Petersen RC, Kokmen E, Kurland LT, et al. The Mini-Mental State Examination in general medical practice: clinical utility and acceptance. *Mayo Clin Proc* 1996; 71: 829–37.
- Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? *Brain* 2006; 129: 729–35.
- Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. *Arch Clin Neuropsychol* 1999; 14: 167–77.
- Troyer AK, Moscovitch M, Winocur G, Alexander MP, Stuss D. Clustering and switching on verbal fluency: the effects of focal frontal- and temporal-lobe lesions. *Neuropsychologia* 1998a; 36: 499–504.
- Troyer AK, Moscovitch M, Winocur G, Leach L, Freedman M. Clustering and switching on verbal fluency tests in Alzheimer's and Parkinson's disease. *J Int Neuropsychol Soc* 1998b; 4: 137–43.
- Whitehouse PJ, Hedreen JC, White CLIII, et al. Basal forebrain neurons in the dementia of Parkinson disease. *Ann Neurol* 1983; 13: 243–8.
- Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. *CNS Drugs* 2006; 20: 477–505.
- Zetuský WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. *Neurology* 1985; 35: 522–6.